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Objectives: One of the defining features of the novel coronavirus 
disease 2019 infection has been high rates of venous thrombo-
ses. The present study aimed to describe the prevalence of ve-
nous thromboembolism in critically ill patients receiving different 
regimens of prophylactic anticoagulation.
Design: Single-center retrospective review using data from 
patients with confirmed severe acute respiratory syndrome coro-
navirus 2 requiring intubation.
Setting: Tertiary-care center in Indianapolis, IN, United States.
Patients: Patients hospitalized at international units Health Metho-
dist Hospital with severe acute respiratory syndrome coronavirus 
2 requiring intubation between March 23, 2020, and April 8, 2020, 
who underwent ultrasound evaluation for venous thrombosis.
Interventions: None.
Measurements and Main Results: A total of 45 patients were 
included. Nineteen of 45 patients (42.2%) were found to have 
deep venous thrombosis. Patients found to have deep venous 
thrombosis had no difference in time to intubation (p = 0.97) but 
underwent ultrasound earlier in their hospital course (p = 0.02). 
Sequential Organ Failure Assessment scores were similar be-
tween the groups on day of intubation and day of ultrasound (p = 
0.44 and p = 0.07, respectively). d-dimers were markedly higher 
in patients with deep venous thrombosis, both for maximum value 
and value on day of ultrasound (p < 0.01 for both). Choice of pro-
phylactic regimen was not related to presence of deep venous 
thrombosis (p = 0.35). Ultrasound evaluation is recommended if 
d-dimer is greater than 2,000 ng/mL (sensitivity 95%, specificity
46%) and empiric anticoagulation considered if d-dimer is greater
than 5,500 ng/mL (sensitivity 53%, specificity 88%).
Conclusions: Deep venous thrombosis is very common in crit-
ically ill patients with coronavirus disease 2019. There was no 
difference in incidence of deep venous thrombosis among differ-
ent pharmacologic prophylaxis regimens, although our analysis is 
limited by small sample size. d-dimer values are elevated in the 
majority of these patients, but there may be thresholds at which 
screening ultrasound or even empiric systemic anticoagulation is 
indicated. (Crit Care Med 2020; 48:00–00)
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The United States has over a million identified cases of the novel coronavirus disease 2019 (COVID-19) infec-tion caused by the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) with over 60,000 total deaths (1). 
Given the pathophysiology of cytokine storming and exces-
sive complement activation (2), it stands to reason that one 
of the defining features of COVID-19 has been the increased 
prevalence of deep venous thrombosis (DVT) (3–5). Based on 
current data, it is unclear how use of prophylactic anticoagula-
tion prevents development of DVTs in critically ill COVID-19 
patients. We conducted an analysis to explore if pharmacologic 
prophylactic agents are effective for prevention of clinical ve-
nous thrombosis in critically ill COVID-19 subjects. We also 
evaluated different d-dimer value thresholds associated with 
DVTs that could guide further diagnostic and therapeutic 
interventions for this patient population.
MATERIALS AND METHODS
Patients hospitalized at IU Health Methodist Hospital with 
confirmed SARS-CoV-2 requiring intubation and mechanical 
ventilation between March 23, 2020, and April 8, 2020, were 
identified through electronic medical records. Methodist Hos-
pital is an 802-bed tertiary-care center with 120 ICU beds, af-
filiated with Indiana University School of Medicine. A manual 
chart review was conducted by the primary author (R.T.) 
on identified COVID-19 patients and all who underwent DOI: 10.1097/CCM.0000000000004472
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ultrasound evaluation for DVT were included. Any DVT noted 
in the lower or upper extremities on ultrasound was recorded 
as positive (+) for DVT. The study was approved by the institu-
tional review board at Indiana University School of Medicine.
A data collection form was developed for the systematic re-
trieval of anonymized epidemiologic, historical, diagnostic, 
and treatment data. Age, race, and body mass index (BMI) were 
all noted at time of patient admission. Time from admission 
to intubation as well as time from admission to ultrasound 
evaluation were calculated in days. Sequential Organ Failure 
Assessment (SOFA) was calculated for all patients with data pro-
vided during the time period immediately prior to intubation 
as well as on the day of the ultrasound study. d-dimer values 
were also recorded as the value closest to the date of ultrasound 
as well as the overall maximum value during the hospitaliza-
tion. Finally, DVT pharmacologic prophylactic agent and dos-
ing were recorded for all patients at time of the ultrasound.
Baseline variables with normal distributions were described 
as mean and sd and as median and interquartile ranges for 
skewed distribution. Continuous measures were compared using 
Mann-Whitney U test and categorical measures through Pearson 
chi-square test or Fisher exact test. p value of less than 0.05 were 
defined as statistically significant. All analyses were performed 
using Microsoft Excel (Version 16.38; Microsoft, Redmond, WA).
Using the d-dimers recorded for each patient, we calculated 
different thresholds including positive predictive value (PPV), 
negative predictive value (NPV), sensitivity, and specificity as-
sociated with the ultrasound diagnosis of DVT.
RESULTS
Between March 23, 2020, and April 8, 2020, 45 intubated 
patients with COVID-19 underwent ultrasound evaluation 
to identify DVT and were subsequently included in our study. 
Overall incidence of DVT was 19 of 45 or 42.2% with all noted 
TABLE 1. Patient Demographics and Clinical Characteristics
Characteristic Total (n = 45) (+) DVT (n = 19) (–) DVT (n = 26) p
Age, yr, mean (sd) 60.8 (14.9) 64.1 (14) 58.3 (15.4) 0.102
Race, n (%)
 White 14 (31) 5 (26) 9 (35) 0.830
 Black 24 (53) 11 (58) 13 (50)  
 Other 7 (16) 3 (16) 4 (15)  
Body mass index (kg/m2), mean (sd) 33.6 (9.5) 31.8 (5.8) 35.2 (11.3) 0.119
Days from admission to intubation, median (IQR) 1 (0–2) 1 (0–1.5) 1 (0–3) 0.97
Days from admission to DVT ultrasound,  
median (IQR)
7 (4–9) 6 (3.5–7.5) 9 (6–10) 0.02a
Sequential Organ Failure Assessment score, median (IQR)
 Day of intubation 5 (4–6) 6 (4–7) 5 (4–6) 0.44
 Day of DVT ultrasound 5 (4–6) 6 (5–7) 5 (3.25–5.75) 0.07
d-dimer value (ng/mL), median (IQR)
 d-dimer (maximum) 4,046 (2,706–8,912) 6,911 (4,156–13,892) 3,148 (1,751–5,309) < 0.01a
 d-dimer (date of ultrasound) 3,000 (1,861–5,606) 5,606 (2,937–11,867) 2,274 (1,080–3,430) < 0.01a
DVT prophylaxis, n (%)
 LMWH 40 mg every 24 hr 7 (16) 5 (26) 2 (8) 0.35
 LMWH 30 mg q12h 16 (35) 6 (32) 10 (38)  
 LMWH 40 mg q12h 6 (13) 2 (11) 4 (15)  
 UFH 5,000 U q8h 10 (22) 5 (26) 5 (19)  
 UFH 7,500 U q8h 2 (4) 0 (0) 2 (8)  
 Other 4 (9) 1 (5) 3 (12)  
DVT = deep venous thrombosis, IQR = interquartile range, LMWH = low-molecular-weight heparin, q8h = every 8 hr, q12h = every 12 hr, UFH = unfractionated 
heparin.
aSignificance at p < 0.05.
Summary of demographics, clinical characteristics, and pharmacologic DVT prophylaxis for patients admitted to the ICU who underwent DVT ultrasound. LMWH 
and UFH were used for prophylaxis in the majority of cases. One patient who was found to have a DVT was already on a heparin infusion due to recurrent 
clotting of continuous veno-venous hemofiltration filter and three of the patients in the DVT (–) group were on therapeutic bivalirudin drips for veno-venous-
extracorporeal membrane oxygenation.
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findings being lower extremity clot. Table 1 provides the ge-
neral demographics and diagnostic values.
The mean age was 60.8 years with no significant difference 
between the DVT and non-DVT groups (64.1 vs 58.3; p = 
0.102). The mean BMI was 33.6 kg/m2, again with no significant 
difference between the groups (31.8 vs 35.2; p = 0.119). Patients 
in the DVT group had the ultrasound earlier in their hospital 
course compared with non-DVT group (6 vs 9 d; p = 0.02).
SOFA scores on the day of intubation were not different be-
tween the two groups (6 vs 5; p = 0.44). Patients with DVT 
also had similar SOFA scores on the date of the ultrasound (6 
vs 5; p = 0.07). d-dimer values were significantly higher in the 
(+) DVT group, both on the date of ultrasound as well as the 
overall maximum value (p < 0.01 for both).
Table 1 also shows the various pharmacologic DVT prophy-
laxis in both groups. Low-molecular-weight heparin (LMWH) 
dosed at 30 mg every 12 hours was the most commonly used 
medication and dosing. There was no significant difference in 
anticoagulant regimen between the two groups (p = 0.35).
We also used d-dimer values to describe the PPV, NPV, sen-
sitivity, and specificity with respect toward the diagnosis of 
DVT at different cutoff values (Table 2).
DISCUSSION
We found a large proportion of DVTs among our critically ill 
COVID-19 patients, findings similar to several other studies 
looking at COVID-19 patient populations (3–5). However, 
our study results further expand these findings with regards to 
evaluation of specific anticoagulant regimen. Prophylactic reg-
imens consisting of both LMWH and unfractionated heparin 
were seen at different doses and frequencies. We found that 
DVTs occurred in each regimen, and there was no relationship 
between different prophylactic anticoagulation treatment and 
diagnosis of DVT.
We found similar age and racial distribution between our 
two groups and found similar rates of obesity. This is notable 
as obesity is an independent risk factor in general for venous 
thromboembolic disease (6) but does not appear to be associ-
ated with a higher risk of DVT in COVID-19 subjects. The mean 
SOFA scores, although not different between the two groups 
on the date of intubation, trended toward significance on the 
date of ultrasound (6 vs 5; p = 0.07). This raises several ques-
tions, primary of which was what drove the provider to order 
an ultrasound on that specific day? Was it due to generalized 
worsening clinical course or were there specific examination 
TABLE 2. Predictive Values of Different d-Dimer Thresholds
Date of Ultrasound
d-Dimer Greater  
Than (ng/mL)
Positive  
Predictive Value 
Negative  
Predictive Value Sensitivity Specificity
No. of Patients With  
d-Dimer Greater Than
1,000 0.51 1.00 1.00 0.31 37
1,500 0.53 1.00 1.00 0.35 36
2,000 0.56 0.92 0.95 0.46 32
2,500 0.59 0.88 0.89 0.54 29
3,000 0.59 0.74 0.68 0.65 22
3,500 0.68 0.77 0.68 0.77 19
4,000 0.71 0.75 0.63 0.81 17
4,500 0.73 0.73 0.58 0.85 15
5,000 0.71 0.71 0.53 0.85 14
5,500 0.77 0.72 0.53 0.88 13
6,000 0.82 0.71 0.47 0.92 11
6,500 0.80 0.69 0.42 0.92 10
7,000 0.88 0.68 0.37 0.96 8
7,500 0.88 0.68 0.37 0.96 8
8,000 0.88 0.68 0.37 0.96 8
8,500 0.88 0.68 0.37 0.96 8
9,000 1.00 0.68 0.37 1.00 7
9,500 1.00 0.67 0.32 1.00 6
10,000 1.00 0.67 0.32 1.00 6
Calculated positive predictive value, negative predictive value, sensitivity, and specificity at different d-dimer levels noted on day of ultrasound. All 45 patients had 
recorded d-dimer values that were used for calculations.
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findings that prompted the examination? Although we cannot 
answer this for each case, clinical patterns indicate that ultra-
sounds were pursued in these patients due to their severity 
of illness and elevated inflammatory markers, most notably 
d-dimer. Given our study’s retrospective nature, our patient
population was determined by the original provider’s digres-
sion of ordering a DVT ultrasound. Although this may limit
how generalizable our findings are, our incidence of DVT does
match what has been found in other larger studies (7). This
leads us to believe our observations likely are consistent with
this population of critically ill COVID-19 patients.
All of our patients were on some form of chemical prophy-
laxis from the date of their admission, which does distinguish 
our study from others (4). In addition, these regimens were 
personalized based on the patient’s renal function and weight 
at the discretion of the critical care provider caring for the pa-
tient. However, given the novel nature of this disease process 
and the constantly evolving knowledge of its pathophysiology, 
treatment regimens did deviate from what might be otherwise 
usual care in the ICU. Due to ongoing case studies as well as 
likely a component of anecdotal discussion between providers, 
patients were often placed on regimens at higher dosages or 
frequencies than what is commonly used. Although our results 
did not show any significant difference between the regimens, 
our sample sizes were quite small and further data gathering 
might begin to suggest a trend.
Patients in the (+) DVT group had markedly higher d-dimer 
values. d-dimer is a well-known and effective screening tool for 
venous thromboembolism, although most of its utility lies in 
its NPV due to its poor specificity (8). d-dimer has also been 
evaluated specifically in COVID-19 patients as a screening 
tool with 1,500 ng/mL chosen as a possible screening value (4). 
However, both of our patient groups had medians higher than 
this threshold, albeit with very large interquartile ranges. We 
calculated our own testing characteristics at different d-dimer 
thresholds as noted in Table 2. Although the data were recorded 
both as the overall maximum as well as on the date of the ultra-
sound, we believe that the measurements on the date of ultra-
sound are likely better suited as a screening value as these results 
may have prompted the provider to pursue the diagnostic study. 
From our findings, we recommend ultrasound evaluation if 
d-dimer is greater than 2,000 ng/mL (sensitivity 95%, speci-
ficity 46%) and strongly consider empiric therapeutic antico-
agulation if d-dimer is greater than 5,500 ng/mL (sensitivity
53%, specificity 88%). The screening threshold of 2,000 ng/dL
was chosen given increased specificity as compared with the 
1,500 ng/dL threshold (46% vs 35%) with an acceptable drop 
in sensitivity (95% vs 100%). Driving this was an effort to min-
imize exposure for ultrasound technicians. The empiric treat-
ment level of 5,500 ng/dL was chosen for its strong specificity 
of 88% while retaining a sensitivity of 53% as compared with 
cutoffs above it showing a sensitivity of less than 50%.
CONCLUSIONS
DVT is common in critically ill patients with COVID-19. Al-
though d-dimer values are elevated in the majority of these 
patients, there may be thresholds at which screening ultra-
sound evaluation or even empiric systemic anticoagulation 
is indicated. Finally, there was no difference in incidence of 
DVT among different pharmacologic prophylaxis regimens, 
although our analysis is limited by small sample size.
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